Sterne Kessler Goldstein Fox
ATTORNEYS AT LAW

Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millonig
Lawrence B. Bugaisky
Donald J. Featherstone
Michael V. Messinger

Judith U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Heidi L. Kraus
Edward W. Yee
Albert L. Ferro*
Donald R. Banowit
Peter A. Jackman
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Eldora Ellison Floyd
Thomas C. Fiala
Brian J. Del Buono
Virgil Lee Beaston
Kimberly N. Reddick
Theodore A. Wood

Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Christine M. Lhulier
Rae Lynn Prengaman
Jane Shershenovich*
Lawrence J. Carroll*
George S. Bardmesser
Daniel A. Klein*
Jason D. Eisenberg
Michael D. Specht
Andrea J. Kamage
Tracy L. Muller*
LuAnne M. DeSantis
John J. Figueroa
Ann E. Summerfield
Tiera S. Coston*
Aric W. Ledford*

Michael D. Specht
Jessica L. Parezo
Timothy A. Doyle*
Cynthia M. Bouchez
Nicole D. Dretar*
Ted J. Ebersole

Registered Patent Agents•
Karen R. Markowicz
Nancy J. Leith
Helene C. Carlson
Gaby L. Longsworth
Matthew J. Dowd
Aaron L. Schwartz
Mary B. Tung
Katrina Y. Pei Quach
Bryan L. Skelton
Robert A. Schwartzman

Teresa A. Colella
Jeffrey S. Lundgren
Victoria S. Rutherford
Eric D. Hayes
Michelle K. Holoubek
Robert H. DeSelms
Simon J. Elliott
Julie A. Heider
Mita Mukerjee
Scott M. Woodhouse

Of Counsel
Kenneth C. Bass III
Evan R. Smith
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
•Practice Limited to Federal Agencies

OIPE JC34
MAY 07 2004
PATENT & TRADEMARK OFFICE

May 7, 2004

WRITER'S DIRECT NUMBER:
(202) 772-8766
INTERNET ADDRESS:
CLHULIER@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1648

Re: U.S. Utility Patent Application
Application No. 10/685,801; Filed: October 16, 2003
For: **Method for Detecting Viral Inactivating Agents**
Inventors: Allaway *et al.*
Our Ref: 1900.0380001/JMC/CML

Sir:

Transmitted herewith for appropriate action are the following documents:

1. SKGF Cover Letter;

2. Information Disclosure Statement;

3. A listing of the cited documents on form PTO-1449 (**23** sheets, **108** documents);

4. Copies of the cited documents AL1-AP1, AL2-AN2 AND AR1-AS23 (**76** documents); and

5. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Christine M. Lhulier

Christine M. Lhulier
Attorney for Applicants
Registration No. 54,269

JMC/CML/tis
Enclosures

OIPE JC34
MAY 07 2004
PATENT & TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Confirmation No. 5154
Allaway *et al.*	Art Unit: 1648
Appl. No. 10/685,801	Examiner: *To be assigned*
Filed: October 16, 2003	Atty. Docket: 1900.0380001/JMC/CML
For: **Method for Detecting Viral Inactivating Agents**	

Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of documents **AA1-AK1, AA2-AK2** and **AA3-AJ3** are not provided in accordance with the U.S. Patent and Trademark Office pre-OG notice of July 11, 2003, which states "[t]he Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003." A copy of each other document is included.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached Form PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Christine M. Lhulier

Christine M. Lhulier
Attorney for Applicants
Registration No. 54,269

Date: May 7, 2004

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

254901_1.DOC

OIPE JC34
MAY 07 2004
PATENT & TRADEMARK OFFICE

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.	APPLICATION NO.
1900.0380001/JMC/CML	10/685,801
FIRST NAMED INVENTOR	
Allaway *et al.*	
FILING DATE	ART UNIT
October 16, 2003	1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	5,444,044	08/22/1995	Jiang *et al.*			03/26/1992
	AB1	5,464,933	11/07/1995	Bolognesi *et al.*			06/07/1993
	AC1	5,596,497	01/21/1997	Honda			02/16/1995
	AD1	5,656,480	08/12/1997	Wild *et al.*			01/27/1995
	AE1	5,817,767	10/06/1998	Allaway *et al.*			02/24/1993
	AF1	5,840,843	11/24/1998	Jiang *et al.*			06/07/1995
	AG1	6,008,044	12/28/1999	Cotropia			07/01/1998
	AH1	6,013,263	01/11/2000	Barney *et al.*			06/07/1995
	AI1	6,015,881	01/18/2000	Kang *et al.*			05/01/1998
	AJ1	6,017,536	01/25/2000	Barney *et al.*			12/20/1994
	AK1	6,060,065	05/09/2000	Barney *et al.*			06/07/1995

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1	WO 88/08429	11/03/1998	WIPO			Yes No
	AM1	WO 91/09872	07/11/1991	WIPO			Yes No
	AN1	WO 94/02505	02/03/1994	WIPO			Yes No
	AO1	WO 94/28920	12/22/1994	WIPO			Yes No
	AP1	WO 96/19495	06/27/1996	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	1	Allan, J.S., *et al.*, "Strong Association of Simian Immunodeficiency Virus (SIVagm) Envelope Glycoprotein Heterodimers: Possible Role in Receptor-Mediated Activation," *AIDS Res. Hum. Retroviruses 8*:2011-2020, Mary Ann Leibert, Inc., Publishers (Dec. 1992)
	AS	1	Arthos, J., *et al.*, "Identification of the Residues in Human CD4 Critical for the Binding of HIV," *Cell 57*:469-481, Cell Press (May 1989)
	AT	1	Barin, F., *et al.*, "Virus Envelope Protein of HTLV-III Represents Major Target Antigen for Antibodies in AIDS Patients," *Science 228*:1094-1096, Association for the Advancement of Science (May 1985)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1900.0380001/JMC/CML	APPLICATION NO. 10/685,801
	FIRST NAMED INVENTOR Allaway *et al.*	
	FILING DATE October 16, 2003	ART UNIT 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA2	6,068,973	05/30/2000	Barney *et al.*			06/07/1995
	AB2	6,080,791	06/27/2000	Bodian *et al.*			07/24/1992
	AC2	6,150,088	11/21/2000	Chan *et al.*			04/17/1998
	AD2	6,248,574	06/19/2001	Shaffermann			12/13/1989
	AE2	6,258,599	07/10/2001	Gelder			01/14/2000
	AF2	6,333,395	12/25/2001	Barney *et al.*			06/07/1995
	AG2	6,335,017	01/01/2002	Gelder			10/02/2000
	AH2	6,420,545	07/16/2002	Hoxie *et al.*			06/22/1999
	AI2	6,479,055	11/12/2002	Bolognesi *et al.*			06/06/1995
	AJ2	6,506,554	01/14/2003	Chan *et al.*			01/18/2000
	AK2	6,518,013	02/11/2003	Barney *et al.*			06/07/1995

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL2	WO 00/06599	02/10/2000	WIPO			Yes No
	AM2	WO 00/40616	07/13/2000	WIPO			Yes No
	AN2	WO 03/072028 A2	09/04/2003	WIPO			Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	2	Bosch M.L., *et al.,* "Identification of the fusion peptide of primate immunodeficiency viruses," *Science 244*:694-697, American Association for the Advancement of Science (1989)
	AS	2	Broder, C.C., and Dimitrov, D.S., "HIV and the 7-Transmembrane Domain Receptors," *Pathobiol. 64*:171-179, Karger (1996)
	AT	2	Callahan, L.N., *et al.,* "Dextran Sulfate Blocks Antibody Biding to the Principal Neutralizing Domain of Human Immunodeficiency Virus Type 1 without Interfering with sp120-CD4 Interactions," *J. Virol. 65*:American Society for Microbiology (1991)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1900.0380001/JMC/CML	APPLICATION NO. 10/685,801
	FIRST NAMED INVENTOR Allaway *et al.*	
	FILING DATE October 16, 2003	ART UNIT 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA3	6,605,427	08/12/2003	Wild *et al.*			02/09/2001
	AB3	6,623,741	09/23/2003	Antczak *et al.*			02/29/2000
	AC3	6,667,320	12/23/2003	Bridger *et al.*			12/15/2000
	AD3	6,670,181	12/30/2003	Gelder			11/05/2001
	AE3	6,710,173	03/23/2004	Binley *et al.*			06/23/2000
	AF3	6,716,429	04/06/2004	Sodroski *et al.*			10/01/1998
	AG3	2004/0063637	04/01/2004	Heilman *et al.*			09/16/2003
	AH3	2004/0052820	03/18/2004	Bolognesi *et al.*			10/08/2002
	AI3	2001/0044183	11/22/2001	Io			07/20/2001
	AJ3	2003/0091594	05/15/2003	Hoxie *et al.*			07/16/2002
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	3	Chan, D.C., and Kim, P.S., "HIV Entry and Its Inhibition," *Cell 93*:681-684, Cell Press (May 1998)
	AS	3	Chan, D.C., *et al.*, "Core Structure of gp41 from the HIV Envelope Glycoprotein," *Cell 89*:263-273, Cell Press (Apr. 1997)
	AT	3	Chen, C-H., *et al.*, "Monoclonal Antibodies That Bind to the Core of Fusion-Active Glycoprotein 41," *AIDS Res. Hum. Retroviruses 16*:2037-2041, Mary Ann Liebert, Inc., Publishers (Dec. 2000)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1900.0380001/JMC/CML	APPLICATION NO. 10/685,801
	FIRST NAMED INVENTOR Allaway *et al.*	
	FILING DATE October 16, 2003	ART UNIT 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	4	Chen, C-H., *et al.*, "A Molecular Clasp in the Human Immunodeficiency Virus (HIV) Type 1 TM Protein Determines the Anti-HIV Activity of gp41 Derivatives: Implication for Viral Fusion," *J. Virol. 69*:3771-3777, American Society for Microbiology (Jun. 1995)
	AS	4	Choe, H., *et al.*, "The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates," *Cell 85*:1135-1148, Cell Press (Jun. 1996)
	AT	4	Clapham, P.R., *et al.*, "Human Immunodeficiency Virus Type 2 Infection and Fusion of CD4-Negative Human Cell Lines: Induction and Enhancement by Soluble CD4," *J. Virol. 66*:3531-3537, American Society for Microbiology (Jun. 1992)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1900.0380001/JMC/CML	APPLICATION NO. 10/685,801
	FIRST NAMED INVENTOR Allaway *et al.*	
	FILING DATE October 16, 2003	ART UNIT 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	5	Delwart, E.L., *et al.*, "Retroviral envelope glycoproteins contain a "leucine zipper"-like repeat," *AIDS Res. Hum. Retroviruses 6*:703-704, Mary Ann Liebert, Inc. (1990)
	AS	5	Deng, H., *et al.*, "Identification of a major co-receptor for primary isolates of HIV-1," *Nature 381*:661-666, Macmillan Publishers Ltd. (Jun. 1996)
	AT	5	DeVico, A.L., *et al.*, "Monoclonal antibodies raised against covalently crosslinked complexes of human immunodeficiency virus type 1 gp120 and CD4 receptor identify a novel complex-dependent epitope on gp 120," *Virology 211*:583-588, Academic Press (1995)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1900.0380001/JMC/CML	APPLICATION NO. 10/685,801
	FIRST NAMED INVENTOR Allaway *et al.*	
	FILING DATE October 16, 2003	ART UNIT 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	6	Donzella, G.A., *et al.*, "AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor," *Nat. Med. 4*:72-77, Nature Publishing Company (Jan. 1998)
	AS	6	Doranz, B.J., *et al.*, "A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the .beta.-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors," *Cell 85*:1149-1158, Cell Press (Jun. 1996)
	AT	6	Doranz, B.J., *et al.*, "Use of a gp120 Binding Assay To Dissect the Requirements and Kinetics of Human Immunodeficiency Virus Fusion Events," *J. Virol. 73*:10346-10358, American Society for Microbiology (1999)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1900.0380001/JMC/CML	APPLICATION NO. 10/685,801
	FIRST NAMED INVENTOR Allaway *et al.*	
	FILING DATE October 16, 2003	ART UNIT 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	7	Dragic, T., *et al.*, "HIV-1 entry into CD4.sup.+ cells is mediated by the chemokine receptor CC-CKR-5," *Nature 381*:667-673, Macmillan Publishers Ltd. (Jun. 1996)
	AS	7	Earl, P.L., *et al.*, "Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses," *J. Virol. 65*:31-41, American Society for Microbiology (1991)
	AT	7	Earl, P.L., *et al.*, "Epitope Map of Human Immunodeficiency Virus Type 1 gp41 Derived from 47 Monoclonal Antibodies Produced by Immunization with Oligomeric Envelope Protein," *J. Virol. 71*:2674-2684, American Society for Microbiology (Apr. 1997)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1900.0380001/JMC/CML	APPLICATION NO. 10/685,801
	FIRST NAMED INVENTOR Allaway *et al.*	
	FILING DATE October 16, 2003	ART UNIT 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	8	Eckert, D.M., *et al.*, "Inhibiting HIV-1 Entry: Discovery of D-Peptide Inhibitors that Target the gp41 Coiled-Coil Pocket," *Cell 99*:103-115, Cell Press (Oct. 1999)
	AS	8	Eiden, L.E., and Lifson, J.D., "HIV Interactions with CD4: a continuum of conformations and consequences," *Immunol. Today 13*:201-206, Elsevier Science Publishers Ltd. (1992)
	AT	8	Feng, Y., *et al.*, "HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor," *Science 272*:872-877, Association for the Advancement of Science (May 1996)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1900.0380001/JMC/CML	APPLICATION NO. 10/685,801
	FIRST NAMED INVENTOR Allaway *et al.*	
	FILING DATE October 16, 2003	ART UNIT 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	9	Ferrer, M., *et al.*, "Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements," *Nat. Struct. Biol. 6*:953-959, Nature Publishing Group (Oct. 1999)
	AS	9	Folks, T.M., *et al.*, "Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus," *J. Exp. Med. 164*:280-290, Rockefeller University Press (1986)
	AT	9	Freed, E.O., *et al.*, "Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41," *Proc. Natl. Acad. Sci. USA 87*:4650-4654, National Academy of Sciences of the USA (Jun. 1990)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1900.0380001/JMC/CML	APPLICATION NO. 10/685,801
	FIRST NAMED INVENTOR Allaway *et al.*	
	FILING DATE October 16, 2003	ART UNIT 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	10	Furata, R.A., *et al.*, "Capture of an early fusion-active conformation of HIV-1 gp41," *Nat. Struct. Biol. 5*:276-279, Nature Publishing Company (Apr. 1998)
	AS	10	Gallaher, W.R., *et al.*, "A General Model for the Transmembrane Proteins of HIV and Other Retroviruses," *AIDS Res. Hum. Retroviruses 5*:431-440, Mary Ann Leibert, Inc., Publishers (Aug. 1989)
	AT	10	Gendelman, H.E., *et al.*, "Molecular characterization of a polymerase mutant human immunodeficiency virus," *Virology 160*:323-329, Academic Press (1987)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1900.0380001/JMC/CML	APPLICATION NO. 10/685,801
	FIRST NAMED INVENTOR Allaway *et al.*	
	FILING DATE October 16, 2003	ART UNIT 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	11	Haddrick, M., *et al.*, "Production of non-infectious human immunodeficiency virus-like particles which package specifically viral RNA," *J. Virol. Methods 61*:89-93, Elsevier Science (1996)
	AS	11	Hoffman, L.R., *et al.*, "Structure-based Identification of an Inducer of the Low-pH Conformational Change in the Influenza Virus Hemagglutinin: Irreversible Inhibition of Infectivity," *J. Virol. 71*:8808-8820, American Society for Microbiology (1997)
	AT	11	Jiang, S., *et al.*, "A Conformation-Specific Monoclonal Antibody Reacting with Fusion-Active gp41 from the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein," *J. Virol.* 72:10213-10217, American Society for Microbiology (Dec. 1998)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1900.0380001/JMC/CML	APPLICATION NO. 10/685,801
	FIRST NAMED INVENTOR Allaway *et al.*	
	FILING DATE October 16, 2003	ART UNIT 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	12	Jiang, S., *et al.*, "A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody," *J. Virol. Meth. 80*:85-96, Elsevier Science (Jun. 1999)
	AS	12	Katz, E., and Moss, B., "Immunogenicity of recombinant vaccinia viruses that display the HIV type 1 envelope glycoprotein on the surface of infectious virions," *AIDS Res. Hum. Retroviruses 13*:1497-1500, Mary Ann Liebert, Inc. (1997)
	AT	12	Kemble, G.W., *et al.*, "Intermonomer Disulfide Bonds Impair the Fusion Activity of Influenza Virus Hemagglutinin," *J. Virol. 66*:4940-4950, American Society for Microbiology (Aug. 1992)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1900.0380001/JMC/CML	APPLICATION NO. 10/685,801
	FIRST NAMED INVENTOR Allaway *et al.*	
	FILING DATE October 16, 2003	ART UNIT 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	13	Kwong, P.D., *et al.*, "Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody," *Nature 393*:648-659, Nature Pub. Co. (1998)
	AS	13	Lambert, D.M., *et al.*, "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion," *Proc. Natl. Acad. Sci. USA 93*:2186-2191, National Academy of Sciences of the USA (Mar. 1996)
	AT	13	Lifson, J.D., *et al.*, "AIDS Retrovirus Induced Cytopathology: Giant Cell Formation and Involvement of CD4 Antigen," *Science 232*:1123-1127, Association for the Advancement of Science (May 1986)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1900.0380001/JMC/CML	APPLICATION NO. 10/685,801
	FIRST NAMED INVENTOR Allaway *et al.*	
	FILING DATE October 16, 2003	ART UNIT 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	14	Lifson, J.D., *et al.*, "Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein," *Nature 323*:725-728, Macmillan Publishers Ltd. (Oct. 1986)
	AS	14	Lightfoote, M.M., *et al.*, "Structural characterization of reverse transcriptase and endonuclease polypeptides of the acquired immunodeficiency syndrome retrovirus," *J. Virol. 60*:771-775, American Society for Microbiology (1986)
	AT	14	Lu, M., *et al.*, "A trimeric structural domain of the HIV-1 transmembrane glycoprotein," *Nat. Struct. Biol. 2*:1075-1082, Nature Publishing Company (Dec. 1995)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1900.0380001/JMC/CML	APPLICATION NO. 10/685,801
	FIRST NAMED INVENTOR Allaway *et al.*	
	FILING DATE October 16, 2003	ART UNIT 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	15	Muster, T., *et al.*, "A Conserved Neutralizing Epitope on gp41 of Human Immunodeficiency Virus Type 1," *J. Virol. 67*:6642-6647, American Society for Microbiology (Nov. 1993)
	AS	15	Muster, T., *et al.*, "Cross-Neutralizing Activity against Divergent Human Immunodeficiency Virus Type 1 Isolates Induced by the gp41 Sequence ELDKWAS," *J. Virol. 68*:4031-4034, American Society for Microbiology (Jun. 1994)
	AT	15	Rencher, S.D., *et al.*, "Eliciting HIV-1 envelope-specific antibodies with mixed vaccinia virus recombinants," *Vaccine 15*:265-272, Elsevier Science (1997)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1900.0380001/JMC/CML	APPLICATION NO. 10/685,801
	FIRST NAMED INVENTOR Allaway *et al.*	
	FILING DATE October 16, 2003	ART UNIT 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	16	Rossio, J.L., *et al.*, "Inactivation of Human Immunodeficiency Virus Type 1 Infectivity with Preservation of Conformational and Functional Integrity of Virion Surface Proteins," *J. Virol.* *72*:7992-8001, American Society for Microbiology (1998)
	AS	16	Ryu, J.-R. *et al.*, "Development of an in vitro Assay system for Screening of gp41 Inhibitory Compounds," *Mol. Cells 8*:717-723, Springer-Verlag (1998)
	AT	16	Sattentau, Q.J. and Moore, J.P., "Conformational Changes Induced in the Human Immunodeficiency Virus Envelope Glycoprotein by Soluble CD4 Binding," *J. Exp. Med.* *174*:407-415, The Rockefeller University Press (Aug. 1991)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1900.0380001/JMC/CML	APPLICATION NO. 10/685,801
	FIRST NAMED INVENTOR Allaway *et al.*	
	FILING DATE October 16, 2003	ART UNIT 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	17	Sattentau, Q.J., and Moore, J.P., "Human Immunodeficiency Virus Type 1 Neutralization Is Determined by Epitope Exposure on the gp120 Oligomer," *J. Exp. Med. 182*:185-196, The Rockefeller University Press (Jul. 1995)
	AS	17	Slepushkin, V.A., *et al.*, "Investigation of Human Immunodeficiency Virus Fusion Peptides. Analysis of Interrelations Between Their Structure and Function," *AIDS Res. Hum. Retroviruses 8*:9-18, Mary Ann Leibert, Inc., Publishers (Jan. 1992)
	AT	17	Sullivan, N., *et al.*, "CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization," *J. Virol. 72*:4694-4703, American Society for Microbiology (1998)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1900.0380001/JMC/CML	APPLICATION NO. 10/685,801
	FIRST NAMED INVENTOR Allaway *et al.*	
	FILING DATE October 16, 2003	ART UNIT 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	18	Thali, M., *et al.*, "Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding," *J. Virol. 67*:3978-88, American Society for Microbiology (1993)
	AS	18	VanCott, T.C., *et al.*, "Antibodies with Specificity to Native gp120 and Neutralization Activity against Primary Human Immunodeficiency Virus Type 1 Isolates Elicited by Immunization with Oligomeric gp160," *J. Virol. 71*:4319-4330, American Society for Microbiology (June 1997)
	AT	18	Weissenhorn, W., *et al.*, "Atomic structure of the ectodomain from HIV-1 gp41," *Nature 387*:426-430, Macmillan Publishers Ltd. (May 1997)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1900.0380001/JMC/CML	APPLICATION NO. 10/685,801
	FIRST NAMED INVENTOR Allaway *et al.*	
	FILING DATE October 16, 2003	ART UNIT 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	19	White, J.M., and Wilson, I.A., "Anti-Peptide Antibodies Detect Steps in a Protein Conformational Change: Low-pH Activation of the Influenza Virus Hemagglutinin," *J. Cell Biol. 105*:2887-2896, The Rockefeller University Press, Inc. (Dec. 1987)
	AS	19	Wild, C., *et al.*, "A Synthetic Peptide from HIV-1 gp41 Is a Potent Inhibitor of Virus-Mediated Cell-Cell Fusion," *AIDS Res. Hum. Retroviruses 9*:1051-1053, Mary Ann Leibert, Inc., Publishers (Nov. 1993)
	AT	19	Wild, C., *et al.*, "A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition," *Proc. Natl. Acad. Sci. USA 89*:10537-10541, National Academy of Sciences of the USA (Nov. 1992)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1900.0380001/JMC/CML	APPLICATION NO. 10/685,801
	FIRST NAMED INVENTOR Allaway *et al.*	
	FILING DATE October 16, 2003	ART UNIT 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	20	Wild, C., *et al.*, "Peptides corresponding to a predictive .alpha.-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection," *Proc. Natl. Acad. Sci. USA 91*:9770-9774, National Academy of Sciences of the USA (Oct. 1994)
	AS	20	Wild, C., *et al.*, "Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex," *Proc. Natl. Acad. Sci. USA 91*:12676-12680, National Academy of Sciences of the USA (Dec. 1994)
	AT	20	Wild, C., *et al.*, "The Inhibitory Activity of an HIV Type 1 Peptide Correlates with Its Ability to Interact with a Leucine Zipper Structure," *AIDS Res. Hum. Retroviruses 11*:323-325, Mary Ann Leibert, Inc., Publishers (Mar. 1995)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1900.0380001/JMC/CML	APPLICATION NO. 10/685,801
	FIRST NAMED INVENTOR Allaway *et al.*	
	FILING DATE October 16, 2003	ART UNIT 1648

	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	21	Wyatt, R., *et al.,* "Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding," *J. Virol. 69*:5723-5733, American Society for Microbiology (1995)
	AS	21	Yamshchikov, G.V., *et al.,* "Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system," *Virology 21*:50-58, Academic Press (1995)
	AT	21	Database Entrez-PubMed, Abstract for Jiang, S., *et al.*, "A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein," *J. Virol. 72*:10213-10217, American Society for Microbiology (1998)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1900.0380001/JMC/CML	APPLICATION NO. 10/685,801
	FIRST NAMED INVENTOR Allaway *et al.*	
	FILING DATE October 16, 2003	ART UNIT 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	22	Database Entrez-PubMed, Abstract for Jiang, S., *et al.,* "A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody," *J. Virol. Methods 80*:85-96, Elsevier Science (1999)
	AS	22	Database Entrez-PubMed, Abstract for McMahon, J.B., *et al.,* "Development of a cyanovirin-N-HIV-1 gp120 binding assay for high throughput screening of natural product extracts by time-resolved fluorescence," *J. Biomol. Screen. 5*:169-176, Mary Ann Liebert, Inc. (2000)
	AT	22	Database Entrez-PubMed, Abstract for Sunila, I., *et al.,* "gp120 is present on the plasma membrane of apoptotic CD4 cells prepared from lymph nodes of HIV-1-infected individuals: an immunoelectron microscopic study," *AIDS 11*:27-32, Lippincott Williams & Wilkins (1997)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1900.0380001/JMC/CML	APPLICATION NO. 10/685,801
	FIRST NAMED INVENTOR Allaway *et al.*	
	FILING DATE October 16, 2003	ART UNIT 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	23	Database Entrez-PubMed, Abstract for Zhang, W., *et al.,* "Antibody 17b binding at the coreceptor site weakens the kinetics of the interaction of envelope glycoprotein gp120 with CD4," *Biochemistry 40*:1662-1670, American Chemical Society (2001)
	AS	23	International Search Report for International Patent Application No. PCT/US03/32582, mailed April 13, 2004, Alexandria, VA
	AT		

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.